Precipio, INC

Precipio, Inc. will host a Q2-2026 Shareholder Update Call on August 17th, 2026, to discuss core business progress and include a live Q&A session.

Precipio, Inc. announced the results of its Annual Meeting held on June 15, 2026, where stockholders elected new directors and ratified the appointment of its independent auditor.

Precipio, Inc. has scheduled its Q1 2026 shareholder update call for May 18, 2026, featuring a new moderated live Q&A session.

Precipio, Inc. announced preliminary unaudited financials for Q4 and fiscal year 2025, reporting significant revenue growth and a shift to positive Adjusted EBITDA and operating cash flow.

Precipio, Inc. announced executive salary and bonus increases, alongside performance-based stock options tied to a $40 per share stock price target, effective January 1, 2026.

Precipio, Inc. announced it will host a Q3-2025 Shareholder Update Call on November 17, 2025, to discuss updates on its core businesses.

Precipio, a cancer diagnostics company, reported significant revenue growth in Q3 2025 and the nine months ended September 30, 2025, but continues to face substantial doubt about its ability to continue as a going concern.

Precipio, Inc. reported a net income of $74,000 for Q2 2025, driven by a 27% increase in net sales and non-recurring income, despite ongoing operating losses and significant accumulated deficit.

Precipio Inc. saw a significant revenue increase in the first quarter of 2025, but faces ongoing concerns about its ability to continue as a going concern.

Precipio Inc. saw a revenue increase in Q3 2024, driven by higher diagnostic testing volumes, but ongoing losses and a working capital deficit raise concerns about its financial stability.

Precipio Inc. saw a significant increase in diagnostic testing revenue in the second quarter of 2024, driven by a 92% increase in cases processed, but continues to face financial challenges.

Precipio Inc. saw a 22% increase in net sales in Q1 2024 compared to Q1 2023, driven by higher diagnostic testing volumes, but the company still faces substantial doubt about its ability to continue as a going concern.

Precipio's 2024 annual report shows revenue growth driven by increased diagnostic testing, but substantial doubt remains about the company's ability to continue as a going concern.

Precipio Inc.'s 10-K filing reveals a net loss of $5.8 million for 2023 and substantial doubt about the company's ability to continue as a going concern.

Christina Rizopoulos Valauri, a Director of Precipio, Inc., received 108 shares of common stock on July 15, 2026.

Jeffrey Cossman, a Director of Precipio, Inc., received 416 shares of common stock on July 15, 2026.

David Seth Cohen, a Director of Precipio, Inc., received 520 shares of common stock on July 15, 2026.

Richard A. Sandberg, a Director at Precipio, Inc., reported a transaction involving the sale of 900 shares of common stock.

Richard A. Sandberg, a Director at Precipio, Inc., reported transactions involving the sale of common stock on May 19th and May 20th, 2026.

Director Christina Valauri received 93 shares of Precipio common stock in lieu of cash compensation for Q1 2025 board service.

Precipio, Inc. has announced its 2026 Annual Meeting of Stockholders, to be held virtually on June 15, 2026, with key proposals including director elections and auditor ratification.

Precipio, Inc. is urgently requesting shareholders to instruct their brokers to vote immediately to ensure quorum for its annual meeting and avoid significant rescheduling costs.

Precipio, Inc. has filed a definitive proxy statement with the SEC, soliciting material pursuant to Section 240.14a-12.

Precipio, Inc. will hold its 2025 Annual Meeting of Stockholders virtually on June 17, 2025, to elect directors and ratify the appointment of its accounting firm.

Precipio, Inc.'s 2024 Annual Meeting of Shareholders was adjourned due to the absence of a quorum and will resume virtually on June 21, 2024.

Precipio, Inc. is requesting shareholders to vote their shares by 11 p.m. Eastern Time on June 12th to ensure quorum for the annual shareholders meeting and avoid potential rescheduling costs of up to $100,000.

Leviticus Partners LP has reported a passive 9.1% beneficial ownership stake in Precipio, Inc. common stock as of December 31, 2025.

Leviticus Partners LP has disclosed a 9.3% beneficial ownership stake in Precipio, Inc. through a Schedule 13G filing.

Leviticus Partners LP has disclosed an 8.0% passive beneficial ownership stake in Precipio, Inc. common stock.